Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin®-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients
One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX®-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary
The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.FESILTY complements Grifols' bleeding
Chronos‑PD shows that biological changes associated with Parkinson's disease (PD) can emerge up to 12 years before clinical diagnosisUncovered reproducible early molecular signals and distinct molecular patterns in PD,
Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value
Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts
‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart
Urges Improved Disclosure Around Key Issues for the Benefit of Grifols Shareholders
Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols
Urges Board to Prove its Independence by Accepting Tomas Daga's Voluntary Resignation
Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols
SAN CARLOS, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a
Believes Substantially Greater Value Than Any Brookfield Bid Can Be Realized by Ousting Conflicted Directors and Restoring Majority Control of Independent Shareholders
Demands Rightful Addition of Paul Herendeen to
Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation
Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value
Believes Rumored Brookfield
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management treatments form part of
Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare agent A successful
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen's recombinant
Hagens Berman urges investors in Grifols, S.A. American Depositary Shares (NASDAQ:GRFS) who suffered substantial losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/grfs
Contact the Firm Now:
